PROGRAM

IMPLEMENTATION
REVIEW
MEDICINE ACCESS
PROGRAMS

MARY LOVE V. SALVE, RPh

Pharmacist II – CSPMAP PH Coor
 Program Accomplishment
2022-2023 (2nd Quarter)

Cancer Support and Palliative Care Medicine

Access Program
Cancer Support and Palliative Care Medicines Access
Program

PATIENT STATUS
Category
Total from January
to June 2023
Newly Enrolled 618
Completed Treatment/ Survival 91
Abandoned/ Lost to follow-up 0
treatment
Deceased 20
Ongoing Treatment 304

Program Accomplishment 2023 (2nd Quarter)

Cancer Support and Palliative Care Medicines Access
Program

CSPMAP Patient Status in RIZAL MEDICAL CENTER

400
350
300
250
200
150
100
50
0
d l t t
ll e iv va en ed le
d
en
o m as ol m
En
r
Sur at ce en
r at
y t/ tr e De s r e
wl en p e nt g
T
Ne m -u ti in
eat ll o
w pa g o
T r fo ro
f On
ed to be
et st um
pl L o
m / lN
Co ned ta
o To
a nd
Ab

20222 2023 Total as of June 2023

Instruction: Include a graph for your data comparing number of cases in 2021 and
2022 as shown below. Program Accomplishment 2023 (2nd Quarter)
 B. CANCER DIAGNOSES MATRIX
Complete Final Cancer Diagnosis 2022 Jan – June 2023 Total Number of Patients (2022 to June
2023)

Breast Cancer 119 359 478

Blood Cancer 3 16 19

Childhood Cancer 2 8 10

Colorectal Cancer 0 76 76

Digestive Tract Cancer 0 24 27

Gynecologic Cancer 7 88 95

Head & Neck Cancer 1 30 31

Thyroid Cancer 0 1 1

Lung Cancer 0 5 5

Prostate Cancer 1 3 4

Bladder Cancer 0 0 0

Others: (Specify)

Neuroendocrine Tumor 0 2 2

Cutaneous Squamous Cell Cancer 0 1 1

Metaplastic Cancer 0 1 1

Sarcoma 0 1 1

Seminoma 0 2 2

Chondrosarcoma 0 1 1

TOTAL 133 618 751

Cancer Support and Palliative Care Medicines Access
Program

CANCER DIAGNOSES MATRIX

Type of Cancer Total Number of Patients with
Endorsement from Central Office as from
January to June 2023
BREAST CANCER 227
COLORECTAL CANCER 30
HEAD AND NECK CANCER 5
GYNECOLOGIC CANCER 25
BLOOD CANCER 1
DIGESTIVE CANCER 4
LUNG CANCER 1
PROSTATE CANCER 1
TOTAL 294

Program Accomplishment 2023 (2nd Quarter)

Cancer Support and Palliative Care Medicines Access
Program

Cancer Diagnoses as of June 2023 in Rizal Medical Center

250

200

150

100

50

0
R R R R ER R R R
NCE NCE NCE NCE NC NCE NCE NCE
CA CA CA CA CA CA CA CA
AS
T
T AL C K
GI
C
O D IV
E
NG AT
E
E EC NE O LO ES
T L U T
B R R D O L B IG OS
OL
O AN NE
C D PR
C D Y
H EA G

as of June 2023

Program Accomplishment 2023 (2nd Quarter)

Cancer Support and Palliative Care Medicines Access
Program
Status of Medicines
Last few stocks (as of July 13, 2023) Out of stocks
Bleomycin 15 units vial Bicalutamide FC 50 mg tablet
Docetaxel 80 mg vial Calcium Folinate 50 mg vial
Doxorubicin 50 mg vial Carboplatin 450 mg vial
Paclitaxel 6 mg/mL, 25 mL vial Carboplatin 150 mg vial
Gemcitabine 200mg vial Cisplatin 1mg/ml, 10 mL vial
Cisplatin 1mg/ml, 50 mL vial
Cytarabine 100mg/mL, 5mL vial
Docetaxel 20mg/mL, 1mL vial
Doxorubicin 10mg vial
Epirubicin 50mg vial
Etoposide 20mg/ mL vial
Gemcitabine 1g vial
Goserelin 3.6mg depot soln PFS
Idarubicin 5mg
Fast Moving Slow Moving/Non Moving
Anastrazole 1 mg tablet
Bleomycin 15 units vial
Carboplatin 450 mg vial
Cisplatin 1mg/ml, 50 mL vial
Cyclophosphamide 500 mg vial
Docetaxel 80 mg vial
Doxorubicin 50 mg vial
Epoetin alfa 10,000 units PFS
Filgrastim (G-CSF) 300 mcg/0.5 mL
Gemcitabine 1 g vial
L-asparaginase 10,000 units vial
Capecitabine 500 mg tablet
Letrozole 2.5 mg tablet
Ondansetron HCl 2mg/mL, 4 mL amp
Program Accomplishment 2023 (2nd Quarter)
Cancer Support and Palliative Care Medicines Access
Program
Status of Medicines

Few stocks Out of stocks Fast Moving Slow Moving/Non Moving

Bleomycin 15 units vial Imatinib 100 mg tablet Oxaliplatin 50 mg vial Hydroxyurea 500 mg cap

Docetaxel 80 mg vial Rituximab 10mg/ mL, 10 mL vial Paclitaxel 6 mg/mL, 25 mL vial Fluorouracil 50 mg/ mL, 10 mL vial

Paclitaxel 6 mg/mL, 25 mL vial Capecitabine 500 mg tablet Leuproreline acetate 3.75mg PFS

Gemcitabine 200mg vial Cyclophosphamide 500 mg vial MESNA 100mg/mL, 4mL ampul

Irinotecan 40mg/ 2 mL vial Docetaxel 20 and 80 mg vial

Ifosfamide 1g vial Doxorubicin 50 mg vial

Mercatopurine 50mg btablet Filgrastim 300 mcg PFS
Gemcitabine 1g and 200 mg vial

Methotrexate 2.5 mg tablet Imatinib 100 mg tablet

Methotrexate 25 mg/mL, 2mL vial Letrozole 2.5 mg tab

Rituximab 100 mg and 500 mg vial
Tamoxifen 20 mg tab
Rituximab 10mg/ mL, 50 mL vial Trastuzumab 600 mg vial (SC)
Vincristine 1 mg and 2 mg vial

Program Accomplishment 2023 (2nd Quarter)

Cancer Support and Palliative Care Medicines Access
Program
Status of Medicines

Last few stocks (as of July 13, 2023) Out of stocks Fast Moving Slow Moving/Non Moving

Bleomycin 15 units vial Vincristine 1mg/ mL, 1mL vial Capecitabine 500 mg tablet Vinblastine sulfate 1 mg/ mL, 10 mL vial

Docetaxel 80 mg vial Vincristine 1mg/ mL, 2mL vial Cyclophosphamide 500 mg vial

Doxorubicin 50 mg vial Docetaxel 20 and 80 mg vial

Paclitaxel 6 mg/mL, 25 mL vial Doxorubicin 50 mg vial

Gemcitabine 200mg vial Filgrastim 300 mcg PFS

Gemcitabine 1g and 200 mg vial

Imatinib 100 mg tablet

Letrozole 2.5 mg tab

Rituximab 100 mg and 500 mg vial
Tamoxifen 20 mg tab
Trastuzumab 150 mg vial
Trastuzumab 600 mg vial (SC)
Vincristine 1 mg and 2 mg vial

Program Accomplishment 2023 (2nd Quarter)

Cancer Support and Palliative Care Medicines Access
Program
Status of Medicines

Few stocks Out of stocks Fast Moving Slow Moving/Non Moving

L-asparaginase 10,000 units vial

Imatinib 400mg tablet

Program Accomplishment 2023 (2nd Quarter)

Cancer Support and Palliative Care Medicines Access
Program

SUPPLY CHAIN MANAGEMENT BEST PRACTICES

Indicators Facility Best Practices
Storage Practices  All drugs and medicines are placed in one
area (MED ROOM) with ambient temperature
and storage and to prevent mix ups in other
regular D/M
Inventory Practices  Inventory of Drugs and Medicines is done
every M/W/F for better management of stocks
level and inventory
 Use of bin cards which will be tallied with the
electronic data is useful in proper inventory
management

Documentation Practices  Reports are done every end of the month

 All MAPs Drugs and Medicines dispensed to
patients are charged electronically for proper
documentation
Program Accomplishment 2023 (2nd Quarter)
Cancer Support and Palliative Care Medicines Access
Program

SUPPLY CHAIN MANAGEMENT BEST PRACTICES

Program Accomplishment 2023 (2nd Quarter)

Cancer Support and Palliative Care Medicines Access
Program

Facility initiatives/activities for the program:

Cancer Support and Palliative Care Medicines Access
Program

Facility initiatives/activities for the program:

Program Accomplishment 2023 (2nd Quarter)

Cancer Support and Palliative Care Medicines Access
Program

Facility initiatives/activities for the program:

Program Accomplishment 2023 (2nd Quarter)

Cancer Support and Palliative Care Medicines Access
Program

Facility initiatives/activities for the program:

Program Accomplishment 2023 (2nd Quarter)

Cancer Support and Palliative Care Medicines Access
Program

Facility initiatives/activities for the program:

Program Accomplishment 2023 (2nd Quarter)

Cancer Support and Palliative Care Medicines Access
Program

Facility initiatives/activities for the program:

Program Accomplishment 2023 (2nd Quarter)

Cancer Support and Palliative Care Medicines Access
Program

Challenges Action Taken

Service Delivery (Readiness):
• Due to the increasing number of cases of COVID-
19, services were hampered for almost one month
(April 2020)
Health Workforce
• Healthcare workers who have been diagnosed with •
COVID-19 were put in quarantine, thus resulting in
decrease of manpower
 Telemedicine service was introduced to
efficiently continue consultations
 Some patients were temporarily shifted to
oral chemotherapy
 For other patients, Onco Center was opened
on M/W/F to cater infusion chemotherapy
Relievers were provided for the healthcare
workers who contracted COVID-19 (Nurses,
Pharmacists and Admin Assistants)
Cancer Support and Palliative Care Medicines Access
Program
Challenges Encountered During Pandemic
Health Information/ Documentation System
• Submission of reports during pre-pandemic, was in
face to face basis.
• Registration of enrollees to the program was done
manually
Action Taken
 Submission of reports were put electronically
to avoid physical contacts
 Introduction of BCMAP/CSPMAP Registry of
Patients was done electronically (MedCheck)

Access to Essential Medicines

• Allocation of Drugs and Medicines to our institution  Supplemental Procurement of Medicines thru
does not suffice to the needs of our patient hospital for currently out of stock was done
• Delivery of medicines does not meet our needs in time
• Allocation of drugs and medicines does not meet in
what we requested (RIS) (e.g. low allocations for oral
chemo tablets and high allocations on non moving
D/M.)
• Some essential D/M is not included in the program (e.g
Oxaliplatin vial)
Cancer Support and Palliative Care Medicines Access
Program

Challenges Action Taken

Financing
• None

Leadership/ Governance
• None
Cancer Support and Palliative Care Medicines Access
Program

FUTURE PLANS
• Request of Another Cytotoxic Cabinet for Onco Center – (2023-2024)
• Request of additional Bio Refrigerator on Chemo Drugs and Medicines –
(ongoing procurement and approval thru the MCC of Rizal Med)
• Extension of Onco Center – In-patient wing (2024-2025)
• Procurement of vein finder for chemo patients (2023)
• Procurement of orbital shaker (2024)
MENTAL HEALTH MAP
Mental Health Medicine Access Program
 SERVICE-USER STATUS
Category
Total as of June
2023
Newly Enrolled 514
Follow-Up 1,707
 OPD PSYCHIATRY LEADING CAUSES OF CONSULTATION AS OF JUNE 2023
Causes Total Number of Service-User 2023
ANXIETY 555
SLEEPLESSNESS 294
PANIC DISORDER 582
DEPRESSION 381
SUICIDAL IDEATION 114
SCHIZOPHRENIA 376
POST TRAUMATIC STRESS DISORDER 39
 ITEM DESCRIPTIION EXPIRY DATE QTY RECEIVED QTY BALANCED

ALPRAZOLAM 0.50 MG/TABLET NOVEMBER 2023 113 38

BIPERIDEN 2 MG/TABLET FEBRUARY 2025 2,000 0

CLOZAPINE 100 MG/TABLET NOVEMBER 2024 2,300 0

DONEPEZIL 10 MG/TABLET (1ST) NOVEMBER 2023 3,310 2,848

(2ND) NOVEMBER 2024

ESCITALOPRAM 10 MG/TABLET OCTOBER 2025 444 0

FLUPENTIXOL DECANOATE 20 MG/ML AMPULE AUGUST 2026 500 442

FLUPHENAZINE DECANOATE 25 MG/ML AMPULE AUGUST 2024 720 529

FLUOXETINE 20 MG/TABLET NOVEMBER 2024 480 0

HALOPERIDOL 5 MG/ML AMPULE JUNE 2023 325 0

LAMOTRIGINE 100 MG/TABLET SEPTEMBER 2026 2,000 285

LEVETIRACETAM 500 MG/TABLET JULY 2024 2,000 130

MEMANTINE 10 MG/TABLET MAY 2024 5,500 5,470

SODIUM VALPROIC ACID 500 MG/TABLET DECEMBER 2025 2,000 0

SODIUM VALPROIC ACID 250 MG/TABLET JANUARY 2025 2,000 0

OLANZAPINE 10 MG/TABLET JULY 2025 3,500 323

PALIPERIDONE 100 MG/ML PIECES JUNE 2024 500 430
QUETIAPINE 200 MG/TABLET (1ST) JUNE 2024 2,610 2,253

(2ND) OCTOBER 2025

Thank you!